Tampa General First Florida Health System to Adopt Microbot’s LIBERTY System After FDA Clearance
Tampa General Hospital is the first health system in Florida to deploy Microbot Medical’s LIBERTY Endovascular Robotic System after its FDA 510(k) clearance, using the FDA-cleared, single-use robotic platform for peripheral procedures. This partnership targets a U.S. market of 2.5 million procedures and supports April 2026 SIR conference launch.
1. Florida Health System Adoption
Tampa General Hospital has become the first health system in Florida to adopt Microbot Medical’s LIBERTY Endovascular Robotic System following its FDA 510(k) clearance, marking a major commercial endorsement. Hospital leadership highlighted the system’s potential to enhance procedural precision and improve physician safety during peripheral endovascular interventions.
2. System Features and FDA Clearance
The LIBERTY system is the only FDA-cleared, single-use robotic platform for peripheral endovascular procedures, offering remote operation to reduce radiation exposure and improve accuracy. Its design addresses a U.S. market demand of approximately 2.5 million peripheral procedures annually.
3. Commercial Expansion and Market Launch
Microbot Medical commenced a limited market release of LIBERTY in late 2025 and plans a full commercial launch at the Society of Interventional Radiology conference in April 2026. The Tampa General partnership aims to deepen regional case studies and accelerate broader adoption ahead of the full rollout.